Ryan Livingston

Parent company United Therapeutics announced ralinepag’s substantial reduction in worsening clinical events, as well as improving 6MWD and NT-proBNP.

Parent company Eli Lilly has released full data from ACHIEVE-3, indicating superior weight loss and A1C reductions with orforglipron 12 mg and 36 mg.

The supplemental New Drug Application submission comes as a result of positive phase 3 data from the CORE and CORE2 trials or olezarsen in 2025.

The FDA has approved proprietary desmopressin oral solution formulation ET-600 for the treatment of central diabetes insipidus in children.

The list price of all 3 semaglutide drugs will be lowered to $675, marking a reduction of roughly 50% and 35% for Wegovy and Ozempic, respectively.

The phase 3 REDEFINE 4 trial saw CagriSema achieve 23% weight loss, but fail to demonstrate noninferiority to tirzepatide in patients with overweight or obesity.

The new joint guidelines include a clinical classification system, major contributing factors, and recommendations for treatment and follow-up.

These retrospective cohort studies also showed the vaccine’s reduction of heart attack, stroke, and asthma/COPD flare-ups in patients with RSV.

Patients with severe hypertriglyceridemia and MASLD saw reductions in fasting triglyceride and improvements in remnant cholesterol and hepatic fat.

This secondary analysis of the phase 3b SOUL cardiovascular outcomes trial indicates oral semaglutide’s potential capacity to reduce HF events.

These data from the ongoing VESPER-3 phase 2b study highlight PF’3944’s capacity for reducing weight across 4 weekly-monthly dosing arms.

Catch up with major trial results, key FDA approvals, and more.

Catch up with major FDA decisions, key guidelines updates, and more.

Since 1990, the prevalence of individuals with a BMI ≥30 has increased dramatically, and without significant intervention, will continue to do so.

The new approval allows for repeat administration of iDose TR, modifying the existing single-administration label.

The investigational dual GLP-1/GIP receptor agonist resulted in substantial weight loss without plateau after 48 weeks in patients with obesity.

MannKind Therapeutics has announced new starting dose recommendations for patients with type 1 diabetes switching from injected or insulin pump mealtime therapy.

Recent research shows a substantial portion of US youths have increased risk of cardiometabolic diseases due to obesity and overweight.

A cohort study of patients from the Women’s Health Study has highlighted the direct correlation between lipoprotein(a) levels and cardiovascular risk in healthy patients.

The KAI 12L program is now cleared to determine short PR interval, atrial bigeminy, ventricular bigeminy, left axis deviation, and right axis deviation.

These recommendations simultaneously emphasize the efficacy of weight loss drugs and encourage incorporating lifestyle therapy on top of medication.

The report details the disease burden, mortality, and quality of care trends for 5 major risk factors and the 5 leading causes of CVD death.

Bristol Myers Squibb has reported positive results from the ongoing SCOUT-HCM trial, demonstrating mavacamten’s efficacy in reducing Valsalva LVOT.

According to an announcement by parent company Medtronic, the MiniMed Go app is expected to launch in the spring of 2026.

The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.

The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.

The Q4 recap for endocrinology spotlights major FDA decisions, updates to diabetes care standards, and key clinical trial updates.

This updated approval builds on the success of Fibryga’s 2024 approval for AFD, which was based on positive data from the phase 3 FIBRES trial.

Catch up with major FDA decisions, critical conference news, and more.

Data from the ongoing phase 4 PETITE-T1D study, highlighting the substantially reduced progression to stage 3 T1D, headline the application.